| PRECLINICAL | evidence | Tirzepatide vs. Semaglutide for Obesity Treatment. | Tirzepatide | — | 2025-10-23 |
| PRECLINICAL | evidence | Tirzepatide vs. Semaglutide for Obesity Treatment. | Tirzepatide | — | 2025-10-23 |
| PRECLINICAL | evidence | Tirzepatide and the Prevention of Heart Failure in Obesity: A Multi-Center Cohort Study Using the TriNetX Database. | Tirzepatide | — | 2025-10-22 |
| PRECLINICAL | evidence | Molecular Biomarkers and Therapeutic Approach of Patients with Diabetes and Obstructive Sleep Apnea. | Tirzepatide | Glycemic control | 2025-10-21 |
| PRECLINICAL | evidence | Innovative Therapeutic Approaches Targeting Obesity: Can Flavonoids Improve the Efficacy of Anti-Obesogenic Drugs? | Tirzepatide | Weight & fat loss | 2025-10-18 |
| PRECLINICAL | evidence | GLP-1 receptor agonists as an adjunct to bariatric surgery for weight loss and metabolic outcome improvement: a systematic review and meta-analysis. | Tirzepatide | Weight & fat loss | 2025-10-10 |
| PRECLINICAL | evidence | Efficacy and safety of anti-obesity drugs in metabolic dysfunction-associated steatotic liver disease: An updated review. | Tirzepatide | Weight & fat loss | 2025-10-07 |
| PRECLINICAL | evidence | Use of glucagon-like peptide-1 receptor agonists in idiopathic intracranial hypertension : a systematic review. | Tirzepatide | — | 2025-10-07 |
| PRECLINICAL | evidence | From needles to pills: oral GLP-1 therapy enters the obesity arena. | Tirzepatide | — | 2025-10-06 |
| PRECLINICAL | evidence | Treatment Preferences For Comorbid Obesity and Obstructive Sleep Apnea (PRO-CON OSA) Survey: Patient and Provider Preferences for CPAP and/or Tirzepatide. | Tirzepatide | — | 2025-10-05 |
| PRECLINICAL | evidence | LiCl-driven direct synthesis of mono-protected esters from long-chain dicarboxylic fatty acids. | Tirzepatide | — | 2025-10-02 |
| PRECLINICAL | evidence | Unanticipated Adverse Events With Tirzepatide: Three Cases Underscoring the Importance of Postmarketing Monitoring. | Zepbound | — | 2025-10-01 |
| PRECLINICAL | evidence | Weight loss maintenance after tirzepatide cessation in people with overweight/obesity: a real-world follow-up of the phase 3 SURMOUNT-CN trial. | Tirzepatide | — | 2025-10-01 |
| PRECLINICAL | evidence | Novel oral agents in anti-obesity pharmacotherapy: A narrative review. | Zepbound | Weight & fat loss | 2025-10-01 |
| PRECLINICAL | evidence | Effect of Tirzepatide on Heart Failure in Type 2 Diabetes Mellitus and Obesity: A Systematic Review and Meta-Analysis. | Tirzepatide | Glycemic control | 2025-10-01 |
| PRECLINICAL | evidence | Changes in eating behavior and diet-related quality of life in individuals treated with tirzepatide for type 2 diabetes. | Tirzepatide | — | 2025-10-01 |
| PRECLINICAL | evidence | Effect of Tirzepatide in an Adolescent With Early-Onset Obesity, Hyperphagia, and Type 2 Diabetes. | Tirzepatide | — | 2025-10-01 |
| PRECLINICAL | evidence | A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults. | Tirzepatide | Weight & fat loss | 2025-10-01 |
| PRECLINICAL | evidence | Novel Use of Glucagon-Like Peptide-1 (GLP-1) and Dual Glucose-Dependent Insulinotropic Polypeptide (GIP)/GLP-1 Receptor Agonists in Maturity-Onset Diabetes of the Young (MODY). | Tirzepatide | — | 2025-10-01 |
| PRECLINICAL | evidence | Documentation of Compounded GLP-1 Receptor Agonists in a Large Primary Care Dataset. | Mounjaro | Glycemic control | 2025-10-01 |
| PRECLINICAL | evidence | Allodynia and Dysesthesia Associated With Semaglutide and Tirzepatide. | Tirzepatide | — | 2025-10-01 |
| PRECLINICAL | evidence | [Obesity as a chronic disease: the key role of new therapies]. | Tirzepatide | Weight & fat loss | 2025-10-01 |
| PRECLINICAL | evidence | Major Adverse Cardiovascular Event Outcomes in Patients With Obesity and Type 2 Diabetes Undergoing Medical Weight Management. | Tirzepatide | — | 2025-10-01 |
| PRECLINICAL | evidence | The impact of GLP-1 agonists on sleep disorders: spotlight on sleep apnea. | Tirzepatide | Sleep quality | 2025-10-01 |
| PRECLINICAL | evidence | Cost-Effectiveness of Tirzepatide Versus Liraglutide, Both Adjunct to Diet and Exercise, for Patients with Obesity or Overweight: A UK Perspective. | Mounjaro | Weight & fat loss | 2025-10-01 |
| PRECLINICAL | evidence | Gastrointestinal Symptoms in Obesity Therapy: Mechanisms, Epidemiology, and Management Strategies. | Tirzepatide | — | 2025-09-26 |
| PRECLINICAL | evidence | GLP-1 Agonists in Cardiovascular Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies. | Tirzepatide | — | 2025-09-24 |
| PRECLINICAL | evidence | Rethinking the Diabetes-Cardiovascular Disease Continuum: Toward Integrated Care. | Tirzepatide | — | 2025-09-22 |
| PRECLINICAL | evidence | Impact of Incretin-Based Therapy on Skeletal Muscle Health. | Tirzepatide | — | 2025-09-18 |
| PRECLINICAL | evidence | Saving muscle while losing weight: A vital strategy for sustainable results while on glucagon-like peptide-1 related drugs. | Tirzepatide | — | 2025-09-15 |
| PRECLINICAL | evidence | Real-World Safety Concerns of Tirzepatide: A Retrospective Analysis of FAERS Data (2022-2025). | Mounjaro | — | 2025-09-09 |
| PRECLINICAL | evidence | The Impact of Glucagon-like Peptide-1 Receptor Agonists on Erectile Function: Friend or Foe? | Tirzepatide | Glycemic control | 2025-09-05 |
| PRECLINICAL | evidence | Mounjaro: Less than half of England has NHS access to jab months after roll-out, distressing patients and GPs. | Mounjaro | — | 2025-09-04 |
| PRECLINICAL | evidence | Slimming the risks: GLP-1 receptor agonist therapy may reduce in-hospital complications and hospital readmissions rates for hip fractures compared to obese patients not on these medications. | Mounjaro | Weight & fat loss | 2025-09-02 |
| PRECLINICAL | evidence | Compounded incretins in clinical practice: An opinion of the endocrine and metabolism practice and research network of the American College of Clinical Pharmacy. | Tirzepatide | Glycemic control | 2025-09-01 |
| PRECLINICAL | evidence | Can tirzepatide transform HFpEF management in Pakistan? A call for action. | Tirzepatide | — | 2025-09-01 |
| PRECLINICAL | evidence | Medical vs. Surgical Obesity Management: A Narrative Review of Efficacy, Safety, and Long-Term Outcomes. | Tirzepatide | — | 2025-09-01 |
| PRECLINICAL | evidence | Evaluating the Rates of Pancreatitis and Pancreatic Cancer Among GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. | Tirzepatide | Glycemic control | 2025-09-01 |
| PRECLINICAL | evidence | Tirzepatide compared with semaglutide and 10-year cardiovascular disease risk reduction in obesity: post-hoc analysis of the SURMOUNT-5 trial. | Tirzepatide | — | 2025-09-01 |
| PRECLINICAL | evidence | Understanding the activation mechanism of GLP-1R/GIPR by dual agonist Tirzepatide via molecular dynamics and protein-peptide binding. | LY3298176 | Gut barrier & GI healing · preclinical | 2025-09-01 |
| PRECLINICAL | evidence | Hair Loss Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Use: A Systematic Review. | Tirzepatide | — | 2025-09-01 |
| PRECLINICAL | evidence | [Tirzepatide (Mounjaro(R)) : a GIP/GLP-1 receptor dual agonist for the treatment of type 2 diabetes]. | Mounjaro | Glycemic control | 2025-09-01 |
| PRECLINICAL | evidence | The Effects of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists on Polycystic Ovarian Syndrome: A Scoping Review. | Tirzepatide | — | 2025-09-01 |
| PRECLINICAL | evidence | Mounjaro: Discount deal for UK pharmacies to mitigate price hike. | Mounjaro | — | 2025-08-29 |
| PRECLINICAL | evidence | Pharmacogenomics of Tirzepatide: Genomic Insights into Dual GIP/GLP-1 Agonist Response in Type 2 Diabetes and Atherosclerosis. | Tirzepatide | — | 2025-08-25 |
| PRECLINICAL | evidence | A Bivalent Protease-Activated Receptor-Derived Peptide Mimics Neuronal Anti-Apoptotic Activity of Activated Protein C. | Tirzepatide | — | 2025-08-22 |
| PRECLINICAL | evidence | Mounjaro: UK price set to rise by up to 170% after Trump complaint-will patients have to pay? | Mounjaro | — | 2025-08-20 |
| PRECLINICAL | evidence | Drugs and devices for weight management. | Mounjaro | — | 2025-08-04 |
| PRECLINICAL | evidence | Comparison table: Some drugs for weight management. | Zepbound | — | 2025-08-04 |
| PRECLINICAL | evidence | Advancements and challenges in the management of obesity using pharmacotherapy (Review). | Mounjaro | — | 2025-08-01 |